3/23
03:17 am
imcr
Persica Pharmaceuticals Appoints Dr Edward Littler as Executive Chairman and David Watson as Chief Executive Officer [Yahoo! Finance]
Low
Report
Persica Pharmaceuticals Appoints Dr Edward Littler as Executive Chairman and David Watson as Chief Executive Officer [Yahoo! Finance]
3/23
03:00 am
imcr
Persica Pharmaceuticals Appoints Dr Edward Littler as Executive Chairman and David Watson as Chief Executive Officer
Low
Report
Persica Pharmaceuticals Appoints Dr Edward Littler as Executive Chairman and David Watson as Chief Executive Officer
3/17
05:14 pm
imcr
Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting [Yahoo! Finance]
Low
Report
Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting [Yahoo! Finance]
3/17
04:30 pm
imcr
Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting
Low
Report
Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting
3/16
08:43 am
imcr
Immunocore (IMCR) was downgraded by Jefferies Financial Group Inc. from "buy" to "hold". They now have a $33.00 price target on the stock.
Low
Report
Immunocore (IMCR) was downgraded by Jefferies Financial Group Inc. from "buy" to "hold". They now have a $33.00 price target on the stock.
3/3
07:00 am
imcr
Immunocore to present at upcoming investor conferences
Low
Report
Immunocore to present at upcoming investor conferences
3/1
11:32 am
imcr
Is It Time To Revisit Immunocore Holdings (IMCR) After Recent Pipeline Progress? [Yahoo! Finance]
Low
Report
Is It Time To Revisit Immunocore Holdings (IMCR) After Recent Pipeline Progress? [Yahoo! Finance]
2/27
06:26 am
imcr
Immunocore (IMCR) was downgraded by Zacks Research from "strong-buy" to "hold".
Low
Report
Immunocore (IMCR) was downgraded by Zacks Research from "strong-buy" to "hold".
2/26
08:03 am
imcr
Immunocore (IMCR) had its price target raised by Needham & Company LLC from $71.00 to $75.00. They now have a "buy" rating on the stock.
Low
Report
Immunocore (IMCR) had its price target raised by Needham & Company LLC from $71.00 to $75.00. They now have a "buy" rating on the stock.
2/25
02:36 pm
imcr
Immunocore Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Immunocore Q4 Earnings Call Highlights [Yahoo! Finance]
2/25
02:18 pm
imcr
Immunocore Holdings PLC (IMCR) Q4 2025 Earnings Call Highlights: Robust Revenue Growth and ... [Yahoo! Finance]
Low
Report
Immunocore Holdings PLC (IMCR) Q4 2025 Earnings Call Highlights: Robust Revenue Growth and ... [Yahoo! Finance]
2/25
02:06 pm
imcr
Immunocore Holdings plc (IMCR) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
Immunocore Holdings plc (IMCR) Q4 2025 Earnings Call Transcript [Seeking Alpha]
2/25
07:18 am
imcr
Immunocore reports fourth quarter and full year 2025 financial results and provides a business update [Yahoo! Finance]
Low
Report
Immunocore reports fourth quarter and full year 2025 financial results and provides a business update [Yahoo! Finance]
2/25
07:00 am
imcr
Immunocore reports fourth quarter and full year 2025 financial results and provides a business update
Medium
Report
Immunocore reports fourth quarter and full year 2025 financial results and provides a business update
2/19
09:16 am
imcr
Immunocore (NASDAQ:IMCR) was given a new $38.00 price target on by analysts at Mizuho.
Low
Report
Immunocore (NASDAQ:IMCR) was given a new $38.00 price target on by analysts at Mizuho.
2/18
07:30 am
imcr
Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025 [Yahoo! Finance]
Low
Report
Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025 [Yahoo! Finance]
2/18
07:00 am
imcr
Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025
Low
Report
Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025
2/5
07:08 am
imcr
VectorY Therapeutics Appoints Kevin Pojasek, Ph.D., to Board of Directors
Low
Report
VectorY Therapeutics Appoints Kevin Pojasek, Ph.D., to Board of Directors
2/4
08:43 am
imcr
Immunocore (NASDAQ:IMCR) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
Low
Report
Immunocore (NASDAQ:IMCR) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
2/4
04:52 am
imcr
Levicept Announces the Appointment of James Sandy as Chief Development Officer [Yahoo! Finance]
Low
Report
Levicept Announces the Appointment of James Sandy as Chief Development Officer [Yahoo! Finance]
2/4
04:00 am
imcr
Levicept Announces the Appointment of James Sandy as Chief Development Officer
Low
Report
Levicept Announces the Appointment of James Sandy as Chief Development Officer
2/2
04:52 am
imcr
Assessing Immunocore Holdings (IMCR) Valuation After Recent Share Price Volatility [Yahoo! Finance]
Low
Report
Assessing Immunocore Holdings (IMCR) Valuation After Recent Share Price Volatility [Yahoo! Finance]
2/1
07:53 am
imcr
Moderna Refocuses On Rare Diseases As New Leadership Shapes Pipeline [Yahoo! Finance]
Low
Report
Moderna Refocuses On Rare Diseases As New Leadership Shapes Pipeline [Yahoo! Finance]
1/31
01:33 am
imcr
1/30
09:21 am
imcr
Moderna CMO Jacqueline Miller to step down [Yahoo! Finance]
Low
Report
Moderna CMO Jacqueline Miller to step down [Yahoo! Finance]